{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:12:29Z","timestamp":1788549149700,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd010422","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T00:00:00Z","timestamp":1445385600000}}],"reference-count":52,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010422.pub2","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T00:10:32Z","timestamp":1445472632000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sodium channel blockers for neuroprotection in multiple sclerosis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Chunsong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; West China Second University Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurology; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; West China Second University Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; West China Second University Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hospital Management and Health Policy; West China Hospital, Sichuan University; Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,21]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD010422.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1474-4422(10)70131-9","article-title":"Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"9","author":"Kapoor","year":"2010","journal-title":"Lancet Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD010422.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jns.2008.03.019","article-title":"Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine","volume":"274","author":"Kapoor","year":"2008","journal-title":"Journal of Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD010422.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1176\/jnp.23.1.jnpe17","article-title":"Voltage-gated sodium channel gating modifiers: valuable targets for multiple sclerosis treatment","volume":"23","author":"Mahdavi","year":"2011","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"4","key":"10.1002\/14651858.CD010422.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","article-title":"Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders","volume":"9","author":"Mantegazza","year":"2010","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD010422.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0022-510X(98)00322-0","article-title":"Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine","volume":"162","author":"Sakurai","year":"1999","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awl323","article-title":"Axonal protection in multiple sclerosis a particular need during remyelination?","volume":"129","author":"Smith","year":"2006","journal-title":"Brain"},{"issue":"3","key":"10.1002\/14651858.CD010422.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ncpneuro0735","article-title":"Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis current status","volume":"4","author":"Waxman","year":"2008","journal-title":"Nature Clinical Practice. Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0008|cit8","unstructured":"Zhang Z An open label trial of Gabapentin symptoms control in patients with multiple sclerosis Foreign Medical Sciences 1999"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0009|cit9","unstructured":"The neuroprotective effect of lamotrigine and interferon beta 1a in patients with relapsing-remitting multiple sclerosis http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00917839"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0010|cit10","unstructured":"MS-SMART: Multiple sclerosis-secondary progressive multi-arm randomisation trial http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01910259"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0011|cit11","unstructured":"Protective role of oxcarbazepine in multiple sclerosis (PROXIMUS) http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02104661"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000151514","article-title":"The prevalence of multiple sclerosis in the Middle East","volume":"31","author":"Al-Hashel","year":"2008","journal-title":"Neuroepidemiology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.wnl.0000316802.35974.34","article-title":"Temporal trends in the incidence of multiple sclerosis: a systematic review","volume":"71","author":"Alonso","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00019052-200106000-00003","article-title":"Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences","volume":"14","author":"Bjartmar","year":"2001","journal-title":"Current Opinion in Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(12)70059-5","article-title":"Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects","volume":"11","author":"Cohen","year":"2012","journal-title":"Lancet Neurology"},{"issue":"7109","key":"10.1002\/14651858.CD010422.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511401460","article-title":"Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran","volume":"17","author":"Etemadifar","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nurt.2006.10.003","article-title":"Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain","volume":"4","author":"Ettinger","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1080\/09638280701707324","article-title":"A descriptive profile of caregivers of older adults with MS and the assistance they provide","volume":"30","author":"Finlayson","year":"2008","journal-title":"Disability and Rehabilitation"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e318233b240","article-title":"A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS","volume":"77","author":"Freedman","year":"2011","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"8261","DOI":"10.1523\/JNEUROSCI.23-23-08261.2003","article-title":"Calmodulin binds to the C terminus of sodium channels Nav1.4 and Nav1.6 and differentially modulates their functional properties","volume":"23","author":"Herzog","year":"2003","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0024|cit24","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/WCO.0b013e3283460542","article-title":"Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs","volume":"24","author":"Hyland","year":"2011","journal-title":"Current Opinion in Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.wco.0000227034.85576.16","article-title":"Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design","volume":"19","author":"Kapoor","year":"2006","journal-title":"Current Opinion in Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1212\/01.wnl.0000218309.01322.5c","article-title":"Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States","volume":"66","author":"Kobelt","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD010422.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010422.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000367614","article-title":"New multiple sclerosis phenotypic classification","volume":"72","author":"Lublin","year":"2014","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0b013e3181cf6ec0","article-title":"The rising prevalence and changing age distribution of multiple sclerosis in Manitoba","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.wco.0000413319.87092.19","article-title":"Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs","volume":"25 Suppl","author":"Miller","year":"2012","journal-title":"Current Opinion in Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0036|cit36","unstructured":"National MS Society What we know about MS http:\/\/www.nationalmssociety.org\/about-multiple-sclerosis\/what-we-know-about-ms\/who-gets-ms\/index.aspx"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1523\/JNEUROSCI.2003-05.2005","article-title":"Na+-dependent sources of intra-axonal Ca2+ release in rat optic nerve during in vitro chemical ischemia","volume":"25","author":"Nikolaeva","year":"2005","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0043|cit43","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm1074","article-title":"The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions","volume":"10","author":"Rogawski","year":"2004","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jnnp.2011.240432","article-title":"Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis","volume":"82","author":"Blizzard","year":"2011","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0046|cit46","unstructured":"Sterne JAC Egger M Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011) The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1523\/JNEUROSCI.12-02-00430.1992","article-title":"Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger","volume":"12","author":"Stys","year":"1992","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1474-4422(10)70249-0","article-title":"Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions","volume":"9","author":"Thompson","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1517\/14656566.2010.508070","article-title":"Approaches to neuroprotective strategies in multiple sclerosis","volume":"11","author":"Tselis","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD010422.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD010422.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"3","key":"10.1002\/14651858.CD010422.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010422","article-title":"Sodium channel blockers for neuroprotection in multiple sclerosis","author":"Yang","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010422.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:32:37Z","timestamp":1788546757000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010422.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,21]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010422.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,21]]}}}